

Alp ÃœÃ§ok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6695302/publications.pdf>

Version: 2024-02-01

66
papers

3,641
citations

218381
26
h-index

149479
56
g-index

66
all docs

66
docs citations

66
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring discrimination experienced by people with a mental illness: replication of the short-form DISCUS in six world regions. <i>Psychological Medicine</i> , 2023, 53, 3963-3973.	2.7	1
2	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	2.7	10
3	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	2.7	14
4	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	2.5	10
5	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. <i>JAMA Psychiatry</i> , 2022, 79, 260.	6.0	44
6	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 826465.	1.3	13
7	Altered Resting State Functional Connectivity and Its Correlation with Cognitive Functions at Ultra High Risk for Psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2022, 321, 111444.	0.9	5
8	Menstrual Cycle-Related Changes in Women with Schizophrenia: A Resting-State fMRI Study. <i>Neuropsychobiology</i> , 2022, , 1-15.	0.9	2
9	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
10	Validation of the Turkish version of the self-evaluation of negative symptoms scale (SNS). <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 221-227.	1.2	2
11	Reliability and validity of the Turkish version <scp>of comprehensive</scp> assessment of at risk mental states. <i>Microbial Biotechnology</i> , 2021, 15, 1028-1032.	0.9	3
12	Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultraâ€high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 966-974.	0.9	8
13	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.1	18
14	Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1 β levels in patients with schizophrenia spectrum disorder and their siblings. <i>Schizophrenia Research</i> , 2021, 229, 27-37.	1.1	14
15	Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder. <i>International Clinical Psychopharmacology</i> , 2021, 36, 89-96.	0.9	7
16	Formal thought disorder in patients with first-episode schizophrenia: Results of a one-year follow-up study. <i>Psychiatry Research</i> , 2021, 301, 113972.	1.7	7
17	Treatment principles of first-episode psychosis. <i>Noropsikiyatri Arsivi</i> , 2021, 58, S12-S16.	0.2	1
18	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	4.1	23

#	ARTICLE	IF	CITATIONS
19	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. <i>Psychological Medicine</i> , 2020, 50, 1884-1897.	2.7	28
20	Lower prepulse inhibition in clinical high-risk groups but not in familial risk groups for psychosis compared with healthy controls. <i>Microbial Biotechnology</i> , 2020, 14, 196-202.	0.9	12
21	Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. <i>Schizophrenia Research</i> , 2020, 225, 31-38.	1.1	4
22	M209. TO WHOM WE PRESCRIBE LONG ACTING ANTIPSYCHOTICS AT DISCHARGE FROM HOSPITAL?. <i>Schizophrenia Bulletin</i> , 2020, 46, S216-S216.	2.3	0
23	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 960-965.	2.3	46
24	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. <i>European Neuropsychopharmacology</i> , 2019, 29, 947-959.	0.3	60
25	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. <i>Frontiers in Psychiatry</i> , 2019, 10, 676.	1.3	5
26	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. <i>World Psychiatry</i> , 2019, 18, 173-182.	4.8	127
27	Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. <i>Psychiatry Research</i> , 2019, 275, 149-154.	1.7	30
28	S105. RELATIONSHIP BETWEEN FORMAL THOUGHT DISORDER, AND FUNCTIONING IN INDIVIDUALS WITH ULTRA HIGH RISK FOR PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S347-S347.	2.3	0
29	Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls. <i>Journal of Psychiatric Research</i> , 2019, 111, 169-185.	1.5	17
30	Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 3-5.	0.9	1
31	Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 1029-1039.	1.5	3
32	Relationship of obsessive-compulsive symptoms to clinical variables and cognitive functions in individuals at ultra high risk for psychosis. <i>Psychiatry Research</i> , 2018, 261, 332-337.	1.7	14
33	Relationship Between Persistent Negative Symptoms and Findings of Neurocognition and Neuroimaging in Schizophrenia. <i>Clinical EEG and Neuroscience</i> , 2018, 49, 27-35.	0.9	28
34	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. <i>Schizophrenia Research</i> , 2017, 186, 19-28.	1.1	110
35	Deficits in Go and NoGo P3 potentials in patients with schizophrenia. <i>Psychiatry Research</i> , 2017, 254, 126-132.	1.7	16
36	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	4.0	685

#	ARTICLE	IF	CITATIONS
37	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. <i>CNS Drugs</i> , 2016, 30, 997-1006.	2.7	12
38	Lack of progressive reduction in P3 amplitude after the first episode of schizophrenia: A 6-year follow-up study. <i>Psychiatry Research</i> , 2016, 243, 303-311.	1.7	5
39	Validation of Turkish version of brief negative symptom scale. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 265-271.	1.2	29
40	Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. <i>International Clinical Psychopharmacology</i> , 2015, 30, 290-295.	0.9	78
41	Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study. <i>Nordic Journal of Psychiatry</i> , 2015, 69, 1708-1714.	0.7	14
42	History of childhood physical trauma is related to cognitive decline in individuals with ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2015, 169, 199-203.	1.1	37
43	Clinical variables associated with suicide attempts in schizophrenia before and after the first episode. <i>Psychiatry Research</i> , 2015, 229, 252-256.	1.7	46
44	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	2.3	229
45	Evaluation of Incidence and Clinical Features of Antibody-Associated Autoimmune Encephalitis Mimicking Dementia. <i>Behavioural Neurology</i> , 2014, 2014, 1-4.	1.1	25
46	Obsessive compulsive symptoms are related to lower quality of life in patients with Schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 243-247.	1.2	10
47	Treatment Guidelines for Patients with Schizophrenia or Psychotic Disorder who are Hospitalized in a Psychiatry Clinic. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 276-288.	0.9	6
48	Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study. <i>Schizophrenia Research</i> , 2014, 158, 241-246.	1.1	47
49	Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia. <i>Schizophrenia Research</i> , 2013, 151, 265-269.	1.1	43
50	Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. <i>Psychiatry Research</i> , 2013, 209, 333-339.	1.7	16
51	The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with first episode schizophrenia. <i>Microbial Biotechnology</i> , 2013, 7, 414-420.	0.9	60
52	Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 449-457.	0.7	27
53	Obsessive compulsive disorder and symptoms may have different effects on schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 429-433.	2.5	38
54	Remission after first-episode schizophrenia: Results of a long-term follow-up. <i>Psychiatry Research</i> , 2011, 189, 33-37.	1.7	51

#	ARTICLE	IF	CITATIONS
55	Antistigma Efforts in Turkey: The Turkish Program Against Stigmatization and Discrimination Because of Schizophrenia as a Part of the World Psychiatric Association Global Program. <i>International Journal of Mental Health</i> , 2007, 36, 58-65.	0.5	2
56	Sexual dysfunction in patients with schizophrenia on antipsychotic medication. <i>European Psychiatry</i> , 2007, 22, 328-333.	0.1	91
57	Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 704-707.	1.1	34
58	Factors Associated with Dropout and Noncompliance in Patients with Schizophrenia: Results of a One-Year Follow-Up. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 161-167.	1.4	3
59	Electroconvulsive Therapy in First-Episode Schizophrenia. <i>Journal of ECT</i> , 2006, 22, 38-42.	0.3	24
60	The impact of antistigma education on the attitudes of general practitioners regarding schizophrenia*. <i>Psychiatry and Clinical Neurosciences</i> , 2006, 60, 439-443.	1.0	48
61	One year outcome in first episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 37-43.	1.8	117
62	Disability in schizophrenia: Clinical correlates and prediction over 1-year follow-up. <i>Psychiatry Research</i> , 2005, 135, 103-111.	1.7	46
63	Attitudes of psychiatrists toward patients with schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 89-91.	1.0	70
64	Cigarette smoking among patients with schizophrenia and bipolar disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 434-437.	1.0	64
65	Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. <i>Journal of Psychiatric Research</i> , 2004, 38, 163-168.	1.5	71
66	Other people stigmatizeâ€¦ but, What about us? Attitudes of Mental Health Professionals towards Patients with Schizophrenia. , 0, , 147-159.		1